Teva Pharmaceutical Industries Ltd (TEVA)
TEVA (NYSE:Drugs)
$40.23
+0.27
+0.68%
Today's Range: 40.00 - 40.45 |
TEVA Avg Daily Volume: 4,088,800
| Last Update: 05/17/13 - 4:03 PM EDT |
| Volume: 3,452,947 |
| YTD Performance: 7.74%
|
| Open: $40.12 |
| Previous Close: $39.96 |
| 52 Week Range: $36.63 -
$42.83 |
| Oustanding Shares: 852,000,000 |
| Market Cap: 34,045,920,000 |
6-Month Chart
TheStreet Ratings Grade for TEVA
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
10 |
9 |
10 |
11 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
15 |
14 |
13 |
14 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.19 |
2.21 |
2.13 |
2.12 |
| Latest Dividend: |
0.27 |
| Latest Dividend Yield: |
2.38% |
| Dividend Ex-Date: |
05/16/13 |
| Price Earnings Ratio: |
17.76 |
|
| Price Earnings Comparisons: |
| TEVA |
Sector Avg. |
S&P 500 |
| 17.76 |
19.90 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
4.93%
|
3.71%
|
-29.19%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
10.90 |
0.46 |
0.13 |
| Net Income |
-30.80 |
-0.05 |
-0.02 |
| EPS |
-27.20 |
-0.02 |
-0.01 |
| Earnings for TEVA: |
| EBITDA |
5.89B |
| Revenue |
20.32B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.21 |
$1.30 |
$5.05 |
$5.46 |
| Number of Analysts |
17 |
17 |
18 |
17 |
| High Estimate |
$1.32 |
$1.33 |
$5.17 |
$5.94 |
| Low Estimate |
$1.13 |
$1.27 |
$4.96 |
$4.86 |
| Prior Year |
$1.28 |
$1.28 |
$5.35 |
$5.05 |
| Growth Rate (Year over Year) |
-5.47% |
1.24% |
-5.58% |
8.05% |
| Apr 02, 2013 | 3:00 PM EDT
If you're overly cautious about biotech, you could incur some major opportunity costs.
Mar 18, 2013 | 7:59 AM EDT
TEVA was downgraded from Outperform to Market Perform, Wells Fargo said. Company is facing increased competition and price erosion in t...
Feb 08, 2013 | 7:44 AM EST
TEVA was downgraded to Hold, Canaccord Genuity said. $45 price target. Company turnaround is taking longer than expected.
| Feb 07, 2013 | 8:28 AM EST
Until we see a session close below 1498.25, a near-term change in direction is unlikely.
| Dec 26, 2012 | 3:00 PM EST
Keep an eye on M&A action in biotech.
Dec 03, 2012 | 8:18 AM EST
Shares of TEVA now seen reaching $50, according to Credit Suisse. Estimates also cut, given the company's new guidance. Outperform rati...
Dec 03, 2012 | 8:03 AM EST
TEVA was downgraded to Neutral from Buy, UBS said. $41 price target. Company's transition will take time.
| Nov 26, 2012 | 10:00 AM EST
These are quality stocks, and they’d be sure to fall on a military escalation with Iran.
| Nov 02, 2012 | 8:30 AM EDT
Here's a quick roundup of earnings from stocks we've recommended. The news has been uniformly good.
| Oct 26, 2012 | 2:30 PM EDT
In the healthcare sector, TMO and TEVA are well positioned to ride out the market’s current volatility.
